AbbVie wins a 5-year free pass on mega-blockbuster Humira in biosim settlement with rival Amgen
It was clear from a recent sit-down with Leerink’s Geoffrey Porges that AbbVie was feeling good about keeping its mega-blockbuster Humira franchise in the US to itself through 2022. And this morning we got a peek into why they were so bullish.
Amgen, which scored the first approval for a biosimilar of Humira in the US, has signed off on a settlement agreement with AbbVie that will delay its rollout until early 2023. Amgen can get started in the EU in the fall of next year, with a marketing pact that calls on the company to pay royalties to AbbVie.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.